AACR Annual Meeting | Conference

Dr. Scott Tagawa Discusses IMMU-132 in Patients With Urothelial Carcinoma

May 31st 2016

Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the antibody-drug conjugate IMMU-132 for the treatment of patients with metastatic platinum-resistant urothelial cancer.

Dr. Barbieri on SPOP Mutations in Prostate Cancer

May 31st 2016

Christopher E. Barbieri, MD, PhD, surgeon, researcher in prostate cancer genomics, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and New-York Presbyterian, discusses the implications of SPOP mutations in patients with prostate cancer.

Dr. Funahashi on Enhanced Activity With Lenvatinib/Everolimus Combo in RCC

May 27th 2016

Yasuhiro Funahashi, MD, senior director, Eisai, discusses a study exploring the enhanced antitumor activity with the combination of lenvatinib (Lenvima) and everolimus (Afinitor) in patients with renal cell carcinoma (RCC).

Dr. Pili on Significance of Entinostat/IL-2 Study in RCC

May 25th 2016

Roberto Pili, MD, professor of Medicine and Robert Wallace Miller Professor of Oncology at Indiana University School of Medicine and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, discusses the significance of the preliminary results of a phase I/II study, which examined the combination of the HDAC inhibitor entinostat and high-dose interleukin-2 (IL-2) in patients with previously untreated metastatic renal cell carcinoma (RCC) of clear cell histology.

Dr. Lutzker on OX40 Agonist in Patients With Refractory Solid Tumors

May 23rd 2016

Stuart Lutzker, MD, PhD, vice president of BioOncology Exploratory Clinical Development, Genentech, discusses results of the first-in-human study of OX40 agonist in patients with refractory solid tumors.

Next Steps With Obesity-Related Genes in Patients With RCC

May 23rd 2016

Julia R. Mendoza-Perez, PhD, visiting scientist, Epidemiology, The University of Texas MD Anderson Cancer Center, discusses next steps and research regarding obesity-related genes in patients with renal cell carcinoma (RCC).

Future Treatment Approaches for Patients With Glioma

May 20th 2016

Melissa L. Bondy, PhD, MS, Duncan Cancer Center-Bondy Cancer Prevention and Population Sciences, Baylor College of Medicine, discusses future treatment approaches for patients with glioma.

Dr. Shah on the HELOISE Study for Gastric Cancer

May 20th 2016

Manish A. Shah, MD, associate professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Bartlett Family Associate Professor in Gastrointestinal Oncology, medical oncologist, Weill Cornell Medicine and New-York Presbyterian Hospital, discusses the phase IIIb HELOISE trial, which compared 2 dose regimens of trastuzumab combined with chemotherapy as a first-line treatment for patients with HER2-positive metastatic gastric/gastroesophageal junction adenocarcinoma (mGC/GEJC).

Dr. Piccart on the MINDACT Study for Early-Stage Breast Cancer

May 19th 2016

Martine J. Piccart, MD, PhD, professor of Oncology, Université Libre de Bruxelles, director of Medicine, Jules Bordet Institute, Brussels, Belgium, discusses the primary analysis of the prospective randomized MINDACT study, which evaluated the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes.

Dr. Drilon on Entrectinib in Patients With Advanced Solid Tumors

May 16th 2016

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses two studies investigating entrectinib in patients with advanced solid tumors.

Dr. Arnedos on the POP Randomized Trial for Early Breast Cancer

May 16th 2016

Monica Arnedos, MD, assistant professor, Department of Medical Oncology, Institut de CancÃ©rologie Gustave Roussy, discusses the Preoperative Palbociclib (POP) Randomized Trial for early-stage breast cancer.

Dr. Ring on Molecular Profiling of CTCs in Advanced Breast Cancer

May 13th 2016

Alexander Ring, MD, graduate student, University of Southern California, discusses a study investigating the molecular profiling of circulating tumor cells (CTCs) as a surrogate for distant metastasis in patients with stage IV breast cancer.

Biomarker Assay as Alternative to Early-Stage Prostate Cancer Detection

May 12th 2016

Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses a study that examined the efficacy of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.

Dr. Hurvitz on Neoadjuvant Therapy for HER2+ Breast Cancer

May 11th 2016

Sara Hurvitz, MD, medical oncologist, General Internal Medicine, Hematology and Oncology at UCLA, discusses neoadjuvant treatment options for patients with HER2-positive breast cancer.

Dr. Infante on AM0010 in Patients With RCC

May 11th 2016

Jeff R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase I study of the novel immunotherapy agent AM0010 and its early promise in patients with renal cell carcinoma.

Dr. Kennedy on RAS as a Target

May 9th 2016

Perry Kennedy, MD, postdoctoral research fellow, H. Lee Moffitt Cancer Center and Research Institute, discusses RAS as a target as well as the NCI RAS Initiative.

Erythrocytes Used as Tumor Antigen Delivery System

May 9th 2016

FranÃ§oise Horand, director, R&D Operations, Erytech Pharma, discusses a study investigating the use of erythrocytes as a tumor antigen delivery system to target antigen-presenting cells and induce efficient immune response against tumors.

Doxorubicin-Loaded Nanoparticle Formulation in Patients With HCC

May 6th 2016

Graham Dixon, PhD, chief scientific officer, Onxeo, discusses a mechanistic study of the relative cytotoxicity of doxorubicin-loaded nanoparticle formulation versus doxorubicin in hepatocellular carcinoma cell lines.

Dr. Desai on BGB-283 in Patients With BRAF or KRAS/NRAS Solid Tumors

May 6th 2016

Jayesh Desai, MD, honorary, Surgery, The Sir Peter MacCallum Department of Oncology, Clinical School-Austin Health, Royal Melbourne Hospital, discusses a phase Ia study exploring BGB-283 in patients with BRAF- or KRAS/NRAS-mutated solid tumors.

Dr. Sharpless on Managing Toxicities With Nivolumab and Ipilimumab in Melanoma

May 5th 2016

Norman E. Sharpless, MD, professor of Medicine and Genetics, chair, the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses how oncologists can best manage toxicities associated with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.